Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer

被引：14
|
作者：
Tone, Mari [1 ]
Izumo, Takehiro [1 ]
Awano, Nobuyasu [1 ]
Kuse, Naoyuki [1 ]
Inomata, Minoru [1 ]
Jo, Tatsunori [1 ]
Yoshimura, Hanako [1 ]
Miyamoto, Shingo [2 ]
Kunitoh, Hideo [2 ]
机构：
[1] Japanese Red Cross Med Ctr, Dept Resp Med, Shibuya Ku, Tokyo, Japan
[2] Japanese Red Cross Med Ctr, Dept Med Oncol, Shibuya Ku, Tokyo, Japan
来源：
LUNG CANCER MANAGEMENT | 2019年 / 8卷 / 02期
关键词：
immune checkpoint inhibitor; NSCLC; salvage chemotherapy; RANDOMIZED PHASE-III; RESPONSE RATES; DOCETAXEL; NIVOLUMAB; PEMBROLIZUMAB; VINORELBINE; CARBOPLATIN; TRIAL; CELLS;
D O I：
10.2217/lmt-2019-0001
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Aim: To assess the relationship of treatment effects between immune checkpoint inhibitor (ICI) and salvage chemotherapy, with the safety profile of salvage chemotherapy. Patients & methods: 18 patients with advanced NSCLC treated using salvage chemotherapy following ICI treatment were retrospectively included. We assessed the overall response rate to and adverse events of salvage chemotherapy. Results: The overall response rate to salvage chemotherapy was 33.3% and that of ICI responders was significantly higher than that of ICI nonresponders (66.7 vs 16.7%, respectively, p = 0.03). The incidence rate of adverse events to salvage chemotherapy was 55.6%. Conclusion: The efficacy of salvage chemotherapy was similar to that preceding ICI. Moreover, the safety of salvage chemotherapy was good.
引用
收藏
页数：7
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF SALVAGE CHEMOTHERAPY FOLLOWING EXPOSURE TO IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Makio, Takechi
    Hara, S.
    Hosoi, K.
    Kinishita, Y.
    Min, K.
    RESPIROLOGY, 2017, 22 : 114 - 115
  • [2] Salvage chemotherapy after treatment with immune checkpoint inhibitors in women with recurrent cervical cancer
    Wallam, Sara
    Dugan, Katherine
    Levinson, Kimberly
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2021, 42 (02) : 394 - 394
  • [3] Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
    Liu, Wei
    Zhang, Lei
    Xiu, Zhiming
    Guo, Jian
    Wang, Liye
    Zhou, Yue
    Jiao, Yang
    Sun, Meiyan
    Cai, Jianhui
    ONCOTARGETS AND THERAPY, 2020, 13 : 7229 - 7241
  • [4] Response to salvage chemotherapy following exposure to immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Leger, Paul Denis
    Rothschild, Sasha
    Castellanos, Emily
    Pillai, Rathi Narayana
    York, Sally Jane
    Horn, Leora
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Safety profile of immune checkpoint inhibitors according to cancer type
    Guerin, Chloe
    Laramas, Mathieu
    Bettega, Francois
    Bocquet, Alexis
    Berton, Elodie
    Lugosi, Maxime
    Bouillet, Laurence
    Toffart, Anne-Claire
    BULLETIN DU CANCER, 2023, 110 (7-8) : 825 - 835
  • [6] Immune checkpoint inhibitors in perioperative treatment in lung cancer
    Horinouchi, Hidehito
    ANNALS OF ONCOLOGY, 2021, 32 : S249 - S249
  • [7] Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
    Onoi, Keisuke
    Chihara, Yusuke
    Uchino, Junji
    Shimamoto, Takayuki
    Morimoto, Yoshie
    Iwasaku, Masahiro
    Kaneko, Yoshiko
    Yamada, Tadaaki
    Takayama, Koichi
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (05)
  • [8] Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?
    Lee, Jiyun
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    JOURNAL OF THORACIC DISEASE, 2020, 12 (07) : 3796 - 3803
  • [9] Do immune checkpoint inhibitors increase sensitivity to salvage chemotherapy?
    Saleh, Khalil
    Khalifeh-Saleh, Nadine
    Kourie, Hampig Raphael
    Nasr, Fadi
    Chahine, Georges
    IMMUNOTHERAPY, 2018, 10 (03) : 163 - 165
  • [10] Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer
    Kuo, Chih-Hsi Scott
    Wang, Chin-Chou
    Huang, Yu-Chen
    Pavlidis, Stelios
    Liu, Chien-Ying
    Ko, How-Wen
    Chung, Fu-Tsai
    Lin, Tin-Yu
    Wang, Chih-Liang
    Guo, Yi-Ke
    Yang, Cheng-Ta
    THORACIC CANCER, 2019, 10 (05) : 1158 - 1166
12345